New antibody drug takes aim at relapsed leukemia

NCT ID NCT07109219

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a new drug called AZD4512 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. The drug is an antibody-drug conjugate that delivers a toxic payload directly to cancer cells. The trial has two parts: first, finding a safe dose, then checking how well it works. About 83 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD4512, an antibody-drug conjugate that targets CD22 on cancer cells
What this could lead to: If it works, this could offer a new treatment option for people with B-cell acute lymphoblastic leukemia that has come back or not responded to other therapies.
What could go wrong: This is an early-phase trial with only 83 participants, so it may not show strong enough results or could have unexpected side effects. The drug is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Contacts and locations

Locations

Research Site
RECRUITING

Duarte, California, 91010, United States
Research Site
WITHDRAWN

Jacksonville, Florida, 32224, United States
Research Site
RECRUITING

Chicago, Illinois, 60611, United States
Research Site
RECRUITING

Iowa City, Iowa, 52242, United States
Research Site
RECRUITING

Franklin, Tennessee, 37067, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
NOT_YET_RECRUITING

Vancouver, British Columbia, V5Z 1M9, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 1X6, Canada
Research Site
NOT_YET_RECRUITING

Guangzhou, 510515, China
Research Site
NOT_YET_RECRUITING

Tianjin, 301600, China
Research Site
RECRUITING

Bunkyō City, 113-8677, Japan
Research Site
RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Seoul, 06591, South Korea
Research Site
RECRUITING

Seoul, 3722, South Korea
Research Site
NOT_YET_RECRUITING

Badalona(Barcelona), 08916, Spain
Research Site
RECRUITING

Barcelona, 08035, Spain
Research Site
RECRUITING

Salamanca, 37007, Spain
Research Site
RECRUITING

Santander, 39008, Spain
Research Site
WITHDRAWN

Valencia, 46026, Spain
Research Site
RECRUITING

Taichung, 40705, Taiwan
Research Site
RECRUITING

Taipei, 106, Taiwan
Research Site
RECRUITING

Bloomsbury, W1T 7HA, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.